
Thoracic organ transplant recipients aged 18–24 years represent a distinct high-risk group with discordant early and longer-term outcomes. After heart transplantation, early survival is relatively favorable, yet 5-year survival conditional on 1-year survival is lowest in this age group among adult recipients and appears descriptively lower than the pediatric age-group estimates. This vulnerability is often attributed to medication nonadherence and care-transition challenges. Although these factors remain important and modifiable, they may not fully explain the excess risk during late adolescence and emerging adulthood. We propose that the 18–24 year period may be a developmental vulnerability window in which neurocognitive and psychological maturation intersects with pharmacokinetic variability, cardiometabolic changes, and transplant-specific stressors. Ongoing maturation of executive function, emotional regulation, identity formation, and self-management capacity may contribute to variable immunosuppressant exposure, missed surveillance, mental-health burden, and disruptions in care continuity. Recognizing this developmental context may improve risk stratification and inform integrated monitoring strategies that combine adherence support with medication-exposure assessment, psychological care, and structured transition. Age-stratified studies are needed to identify the factors that contribute to poor outcomes in this population and determine whether developmentally tailored care improves long-term survival.
Background: Phase-resolved functional lung (PREFUL) magnetic resonance imaging (MRI) is a radiation-free technique that detects regional ventilation and perfusion abnormalities and has shown promise for identifying chronic lung allograft dysfunction (CLAD) in adult lung transplant (LTx) recipients. Its utility in pediatric LTx has not been investigated. We evaluated the feasibility of PREFUL MRI in pediatric LTx recipients and its association with pulmonary function. Methods: In this single-center cross-sectional study, pediatric LTx recipients and healthy controls underwent contrast-free PREFUL MRI at 1.5 T to quantify regional ventilation and perfusion defects. Spirometry and nitrogen multiple-breath washout were performed to determine forced expiratory volume in one second (FEV₁) and lung clearance index (LCI). Group differences were assessed using the rank-sum test, and associations were analyzed using Spearman's correlation. Results: Twenty-two of 24 eligible pediatric LTx recipients (feasibility 92%; median age 13.6 years [range 6–17]; median time since LTx 3.9 years [range 0.6–16.3]) and 11 healthy controls (median age 10.7 years [range 6–15]) completed the study. Perfusion defect extent was significantly greater in pediatric LTx recipients than in controls ( p = 0.001), whereas ventilation defects did not differ ( p = 0.359). No participant met spirometric criteria for CLAD. FEV₁ %predicted, but not FEV₁ % of baseline, correlated inversely with perfusion defect extent ( ρ = -0.487, p = 0.022). No correlations were observed between LCI and MRI-derived ventilation or perfusion parameters. Conclusions: PREFUL MRI is feasible in pediatric LTx recipients and detects regional perfusion abnormalities despite stable spirometry. It may provide a sensitive, radiation-free imaging biomarker for monitoring the pediatric lung allograft.
Background Cardiomyopathy genetic testing is recommended for patients with non-ischemic cardiomyopathy (NICM) but is inconsistently applied once a patient has reached end-stage disease and undergone heart transplantation. Whether a transplant program can systematically test its existing NICM cohort and what completion rate is achievable when testing is operationalized in the clinic rather than offered ad hoc is not well characterized. Methods We studied all 73 adults followed in the Southern Alberta Transplant Program after transplantation for NICM: dilated (DCM), non-dilated left ventricular (NDLVC), restrictive, or hypertrophic (HCM). Cardiomyopathy genetic testing was offered as a program-wide initiative and performed in adulthood using clinically validated multigene panels. Variants were classified by ACMG/AMP criteria; pathogenic or likely pathogenic (P/LP) variants interpreted as explanatory for the recipient's cardiomyopathy were counted as diagnostic. Single heterozygous P/LP variants in autosomal recessive genes were interpreted as carrier findings and not counted toward yield. Yields are reported with Wilson 95% confidence intervals (CIs); the childhood- versus adult-transplant comparison was tested with Fisher's exact test. Results Of 71 eligible patients, 27 (38.0%) had a genetic-testing result before the 12-month operational window; of the 44 offered testing during the window, 37 completed it (84.1%), raising cohort testing coverage to 90.1% (64/71). A diagnostic pathogenic or likely pathogenic (P/LP) variant was identified in 28 of 64 tested patients (43.8%; 95% CI 32.3%-55.9%); a sensitivity analysis restricted to the 36 patients tested with the comprehensive Invitae 121-gene panel yielded an indistinguishable 38.9% (14/36; 95% CI 24.8%-55.1%), with no evidence that variation in panel breadth materially biased the overall estimate. Two additional patients carried a single heterozygous P/LP variant in an autosomal recessive gene (carrier findings, not counted). Yield was higher in patients transplanted in childhood (10/14, 71.4%) than in adulthood (18/50, 36.0%; Fisher's exact P = 0.031). TTN was the most frequent gene (7 P/LP), followed by LMNA, PKP2, and MYH7 (3 each). Conclusions A 12-month program-wide initiative raised cardiomyopathy genetic testing coverage in an existing NICM heart transplant cohort from 38% to 90% by embedding testing in routine transplant clinic visits. The diagnostic yield among tested patients (43.8%) was consistent with published estimates and similar when restricted to the most comprehensive panel, with markedly higher yield in patients transplanted in childhood. These findings provide a reproducible operational template for transplant programs seeking to close the implementation gap in cardiomyopathy genetic evaluation and to enable cascade testing of at-risk relatives.
Background Donation after circulatory death (DCD) is now a major source of cardiac allografts, yet the two dominant recovery strategies, thoraco-abdominal normothermic regional perfusion (NRP) and direct procurement with ex-situ machine perfusion (DP-MP), have never been compared in a dedicated meta-analysis of clinically meaningful endpoints. Methods We systematically searched five databases and grey literature for studies comparing NRP with DP-MP in adult DCD heart transplantation. Random-effects models generated pooled risk ratios (RR), with Hartung–Knapp sensitivity analyses. The primary outcome was severe primary graft dysfunction (PGD); secondary outcomes were survival, treated acute cellular rejection (ACR) and cost. Risk of bias and certainty were assessed with ROBINS-I and GRADE. Results Eight studies were included, three pooled for PGD. NRP was associated with less severe PGD (RR 0.38, 95% CI 0.25–0.60; n = 728; Hartung–Knapp 0.25–0.59) and less treated ACR at one year (RR 0.51, 95% CI 0.35–0.76). Overlapping registry cohorts were de-duplicated; 30-day survival did not differ (RR 1.02, 95% CI 1.00–1.04; P = 0.073), and a borderline one-year difference (RR 1.04, 95% CI 1.00–1.08) was not robust to registry substitution, indicating equivalent survival. Cost favoured NRP; certainty was moderate. Conclusions In adult DCD heart transplantation, thoraco-abdominal NRP was associated with lower rates of severe PGD and treated acute cellular rejection, at equivalent survival and lower cost. As the data are observational, these estimates remain imprecise and subject to residual confounding. NRP is reasonable where feasible, and adequately powered trials with standardised adjudication of graft dysfunction are needed.
Purpose We sought to evaluate the performance of donor-derived cell-free DNA (dd-cfDNA) thresholds and characteristics associated with elevated dd-cfDNA in pediatric heart transplant recipients without rejection by biopsy. Methods Pediatric heart transplant patients with paired endomyocardial biopsy (EMB) and dd-cfDNA (AlloSure) samples from a single center between 12/2022–1/2025 were retrospectively reviewed. Rejection was defined as acute cellular rejection >1A (ACR 1990 ISHLT) or pAMR >0. (While all three are 2004 ISHLT Grade 1R, we considered 1A negative and 1B and 2 positive.)Performance characteristics of elevated dd-cfDNA thresholds for rejection were examined. In patients without rejection, associations of demographic, hemodynamic, laboratory, and imaging characteristics with elevated dd-cfDNA were evaluated. Results There were 118 patients (median age at transplant of 7.4y) with 308 paired EMB and dd-cfDNA assessments. Dd-cfDNA threshold ≥0.2% yielded sensitivity of 74.1% and specificity of 58.7% to predict rejection (AUC 0.74). In the 227 assessments in 100 patients without any rejection; elevated dd-cfDNA was strongly associated with donor-specific antibodies (DSA, 55.7% vs. 16.3%, p<0.0001; DSA median peak MFI 9455 vs. 2401, p=0.003). Of these assessments with coronary angiography, those with elevated dd-cfDNA had a higher proportion of having cardiac allograft vasculopathy compared to those without (17/50 [34.0%] vs. 15/73 [20.5%], p=0.09). Conclusion In patients without rejection, dd-cfDNA is highly correlated with DSA. With elevated dd-cfDNA, possible biopsy-negative rejection and other forms of graft injury must be considered. The clinical significance and management of elevated dd-cfDNA, especially without histopathologic rejection, warrant further study.